Anti-tumor immunity generated by tumor cells engineered to express B7-1 via retroviral or adenoviral gene transfer

Cancer Letters

Volumn 135, Issue 1, 1998, Pages 1-10

  Felzmann, Thomas ^a,b   Ramsey, William J ^a   Blaese, R Michael ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

Author keywords

Anti tumor immunity; Gene therapy; Tumor vaccination

Indexed keywords

B7 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 6; TUMOR ANTIGEN; TUMOR VACCINE;

ADENOVIRUS; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC LYMPHOCYTE; FIBROSARCOMA; FLOW CYTOMETRY; GENE TRANSFER; IMMUNITY; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; TUMOR CELL;

3T3 CELLS; ADENOVIRIDAE; ANIMALS; ANTIGENS, CD80; CANCER VACCINES; CELL SURVIVAL; CELLS, CULTURED; CYTOKINES; CYTOTOXICITY TESTS, IMMUNOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC ENGINEERING; GRAFT REJECTION; HISTOCOMPATIBILITY ANTIGENS CLASS I; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MOLONEY MURINE SARCOMA VIRUS; NEOPLASM TRANSPLANTATION; RETROVIRIDAE; SARCOMA, EXPERIMENTAL; TRANSDUCTION, GENETIC; TRANSGENES; TUMOR CELLS, CULTURED; TUMOR VIRUS INFECTIONS;

MAIZE STREAK VIRUS;

EID: 0032418813     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(98)00274-2     Document Type: Article

References (25)

1. [1] P. Matzinger, Tolerance, danger and the extended family, Annu. Rev. Immunol. 12 (1994) 991-1045.
2. [2] P.S. Linsley, J.A. Ledbetter, The role of the CD28 receptor during T cell responses to antigen, Annu. Rev. Immunol. 11 (1993) 191-212.
3. [3] D.J. Lenschow, T.L. Walunas, J.A. Bluestone, CD28/B7 system of T cells costimulalion, Annu. Rev. Immunol. 14 (1996) 233-258.
4. [4] C.B. Thompson, Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation, Cell 81 (1995) 979-982.
5. [5] T. Boon, J.-C. Cerottini, P. VandenEynden, P. Vanden-Bruggen, A. VanPel, Tumor antigens recognized by T lymphocytes, Annu. Rev. Immunol. 12 (1994) 337-365.
6. [6] S.E. Townsend, J.P. Allison, Tumor rejection after direct costimulation of CD8 + T cells by B7-transfected melanoma cells, Science 259 (1993) 368-370.
7. [7] L. Chen, S. Ashe, W.A. Bradey, Costimulation of antitumor immunity by the B7 counter receptor for the T lymphocyte molecules CD28 and CTLA-4, Cell 71 (1992) 1093-1102.
8. [8] D. Markowitz, S. Goff, A. Bank, A safe packaging line for gene transfer: separating viral genes on two different plasmids, J. Virol. 62 (1988) 1120-1124.
9. [9] F.L. Graham, J. Smiley, W.C. Russel, R. Nairn, Characteristics of a human cell line transformed by DNA from human adenovirus type 5, J. Gen. Virol. 36 (1977) 59-72.
10. [10] N.P. Restifo, F. Esquivel, A.L. Asher, H. Stötter, R.J. Barth, J.R. Bennink, J.J. Mule, J.W. Jewdell, S.A. Rosenberg, Defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an anti-tumor immune response, J. Immunol. 147 (1991) 1453-1459.
11. [11] S.A. Aaronson, C.A. Weaver, Characterization of a murine sarcoma virus (Kirsten) transformation of mouse and human cells, J. Gen. Virol. 13 (1971) 245-252.
12. [12] J.R. Stephenson, S.A. Aaronson, Antigenic properties of murine sarcoma virus-transformed BALB-3T3 nonproducer cells, J. Exp. Med. 135 (1972) 503-515.
13. [13] A.D. Miller, G.J. Rosman, Improved retroviral vectors for gene transfer and expression, BioTechniques 7 (1989) 980-990.
14. [14] T.A. Smith, M.G. Mehaffey, D.B. Kayda, J.M. Saunders, S. Yei, B.C. Trapnell, A. McClelland, M. Kaleko, Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice, Nat. Genet. 5 (1993) 397-402.
15. [15] E.C. Guinan, J.G. Gribben, V.A. Boussiotis, G.J. Freeman, L.M. Nadler, Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity, Blood 84 (1994) 3261-3282.
16. [16] L. Chen, P. McGowen, S. Ashe, J. Johnston, Y. Li, I. Hellström, K.E. Hellström, Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity, J. Exp. Med. 179 (1994) 523-532.
17. [17] D.R. Leach, M.F. Krummel, J.P. Allison, Enhancement of antitumor immunity by CTLA-4 blockade, Science 271 (1996) 1734-1736.
18. [18] G. Dranoff, E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, R.C. Mulligan, Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific and long-lasting anti-tumor immunity, Proc. Natl. Acad. Sci. USA 90 (1993) 3539-3543.
19. [19] C.P. Larsen, S.C. Ritchie, R. Hendrix, P.S. Linsley, K.S. Hathcock, R.L. Hodes, R.P. Lowry, T.C. Pearson, Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7.2) expression on murine dendritic cells, J. Immunol. 152 (1994) 5208-5219.
20. [20] D.J. Schwartzentruber, S.L. Topalian, M. Mancini, S.A. Rosenberg, Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-a and IFNg by human tumor-infiltrating lymphocytes after autologous tumor stimulation, J. Immunol. 146 (1991) 3674-3681.
21. [21] V.K. Kuchroo, M.P. Das, J.A. Brown, A.M. Ranger, S.S. Zamvil, R.A. Sobel, H.L. Weiner, N. Nabavi, L.H. Glimcher, B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy, Cell 80 (1995) 707-718.
22. [22] A. Progador, E. Tzehoval, V.E. Katy, Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunophenotypic competence against parental metastatic cells, Cancer Res. 52 (1992) 3679-3686.
23. [23] A. Progador, R. Bannerji, Y. Watanabe, M. Feldman, E. Gilboa, L. Eisenbach, Anti-metastatic vaccination of tumor-bearing mice with two types of gamma-IFN gene inserted tumor cells, J. Immunol. 150 (1993) 1458-1470.
24. [24] H. Hock, M. Dorsch, U. Kunzendorf, Z. Qin, T. Diamantstein, T. Blankenstein, Mechanism of rejection induced by tumor cell targeted gene transfer of interleukin-2, interleukin-4, interleukin-7, tumor necrosis factor, or interferon-gamma, Proc. Natl. Acad. Sci. USA 90 (1993) 2774-2778.
25. [25] R.I. Tepper, P.K. Pattengale, P. Leder, Murine interleukin-4 displays potent anti-tumor activity in vivo, Cell 57 (1989) 503-512.